Theramex, a leading global speciality pharmaceutical company dedicated to women’s health, is pleased to announce that it has entered into an agreement to acquire the European rights to Duphaston and Femoston from Viatris Inc. Viatris retains the rights for Australia and Japan. The transaction is subject to customary regulatory and anti-trust approvals.
“As we continue to strengthen our commitment to women’s health and improve our patients access to high quality treatments, we are excited to acquire new products to expand our Menopause portfolio.” – Rob Stewart, CEO of Theramex.
Duphaston (dydrogesterone) and Femoston (estradiol/dydrogesterone) may be prescribed in indications related to hormone replacement therapy (HRT).
